Skip to main content
Ascelia Pharma logo

Ascelia Pharma — Investor Relations & Filings

Ticker · ACE ISIN · SE0010573113 LEI · 5493002YR9VCJJPWYN08 ST Manufacturing
Open in API
Filings indexed 295 across all filing types
Latest filing 2020-07-31 Declaration of Voting R…
Country SE Sweden
Listing ST ACE

About Ascelia Pharma

https://www.ascelia.com/

Ascelia Pharma is a biotechnology company focused on developing and commercializing novel drugs for orphan oncology. The company aims to address unmet medical needs for patients with rare cancer conditions. Its lead product candidate, Orviglance, is an oral manganese-based contrast agent for magnetic resonance imaging (MRI). It is designed to improve the detection and visualization of liver metastases, particularly in adult patients with severely impaired kidney function for whom existing contrast agents may be contraindicated. The company's strategy involves identifying, developing, and commercializing innovative treatments for niche cancer-related conditions.

Recent filings

Filing Released Lang Actions
Ändring av antalet aktier och röster i Ascelia Pharma AB
Declaration of Voting Results & Voting Rights Announcements Classification · 99% confidence The document is a press release dated July 31, 2020, titled "Ändring av antalet aktier och röster i Ascelia Pharma AB" (Change in the number of shares and votes in Ascelia Pharma AB). It explicitly states that the number of shares and votes has increased due to a directed new share issue ('riktade nyemissionen') completed on June 30, 2020. It details the new total number of shares and votes as of July 31, 2020. This content directly relates to changes in the company's capital structure and share count, fitting the definition of 'Share Issue/Capital Change' (SHA). Although it is a short announcement, the core subject matter is a capital change, not just the announcement of a report, making SHA a better fit than RPA or RNS.
2020-07-31 Swedish
Declaration of Voting Results & Voting Rights Announcements 2020
Declaration of Voting Results & Voting Rights Announcements Classification · 99% confidence The document details a change in shareholding percentage for a specific holder (Handelsbanken Fonder AB) in an issuer (Ascelia Pharma AB). It explicitly states the 'Reason for major shareholding notification Buy' and provides 'Before the transaction' and 'After the transaction' figures, including the new percentage (5.0293% shares, 5.1112% voting rights). This structure perfectly matches the definition of a Major Shareholding Notification, which corresponds to the code MRQ.
2020-07-02 English
Ascelia Pharma genomför en riktad nyemission om 4 697 781 aktier och tillförs cirka 98,7 MSEK
Share Issue/Capital Change Classification · 98% confidence The document is a press release dated June 30, 2020, announcing that Ascelia Pharma is conducting a 'riktad nyemission' (directed new share issue) to raise approximately 98.7 MSEK. The text explicitly details the issuance of 4,697,781 new shares at 21 SEK per share to institutional investors. This action directly relates to fundraising, capital structure changes, and the issuance of new shares. This aligns perfectly with the definition for 'Capital/Financing Update' (CAP) and also strongly overlaps with 'Share Issue/Capital Change' (SHA). Since the core event is the raising of capital through a new share issue, 'CAP' (Capital/Financing Update) is the most encompassing category for this type of corporate action announcement, although 'SHA' is also highly relevant. Given the focus on raising funds ('tillförs Bolaget cirka 98,7 MSEK') and the mechanism being a new share issue, CAP is selected as the primary classification, as it covers the financing aspect.
2020-06-30 Swedish
Ascelia Pharma completes a directed new share issue of 4,697,781 shares, raising approximately SEK 98.7 million
Capital/Financing Update Classification · 98% confidence The document is a press release dated June 30, 2020, announcing that Ascelia Pharma has completed a 'directed new share issue' raising approximately SEK 98.7 million. The core subject is the issuance of new ordinary shares, which directly relates to changes in the company's capital structure and fundraising activities. This aligns perfectly with the definition of 'Capital/Financing Update' (CAP). Although it involves shares, it is a financing event announcement, not a general share issue/repurchase report (SHA/POS) or a general regulatory filing (RNS). Since it is a specific announcement about raising capital via a share issue, CAP is the most precise classification.
2020-06-30 English
Updated SPARKLE timelines due to Covid-19 impact
Regulatory Filings Classification · 99% confidence The document is titled "PRESS RELEASE" and announces an update to the timelines for the SPARKLE Phase 3 study due to Covid-19 impacts. It provides key operational and timeline changes but does not contain the full financial statements of a 10-K or IR, nor is it a transcript (CT) or a formal dividend notice (DIV). Since it is an announcement regarding operational progress and timeline adjustments, it fits best under the general category for regulatory announcements that aren't strictly financial results (ER) or management changes (MANG). Given the context of providing updates that are material to investors, and since it is a press release format, it is most appropriately classified as a general Regulatory Filing (RNS), as it doesn't fit the more specific categories like CAP, LTR, or TAR. It is not an Earnings Release (ER) as it focuses on clinical trial timelines, not financial performance metrics.
2020-05-20 English
Uppdaterad tidsplan för SPARKLE till följd av Covid-19
Report Publication Announcement Classification · 99% confidence The document is a 'PRESS RELEASE' dated May 20, 2020, announcing an 'Uppdaterad tidsplan' (Updated timeline) for the SPARKLE Phase 3 study due to Covid-19 impacts. It discusses delays in clinical trial results and mentions issues with a CRO. This type of announcement, which communicates material operational or strategic updates outside of standard periodic financial reports (like 10-K or IR), often falls under general regulatory announcements or specific operational updates. Since it is not a formal financial report (10-K, IR), an earnings release (ER), or a specific transaction (DIV, CAP, TAR), it best fits the general regulatory/miscellaneous category, RNS, or potentially a Capital/Financing Update (CAP) if the CRO liquidity issue was framed as a major financial risk, but the primary focus is operational timeline adjustment. Given the context of updating timelines and operational status, and the explicit mention that the information is subject to EU Market Abuse Regulation disclosure requirements, RNS (Regulatory Filings) is the most appropriate general classification for this type of material, non-standardized announcement.
2020-05-20 Swedish

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.